SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jun 2, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $644K total
Actionable Insight • Neutral

The sales are routine post-exercise liquidity events at trivial scale. No bearish read-through. Monitor for any material insider buying (which would be a stronger signal) or for upcoming earnings/catalyst news that could shift sentiment.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$91.84
T+0 close · Jun 2, 2026 · via day close
Latest settled
+8.62%
T+60 · $99.75
Vs SPY
+6.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $91.84entry
  2. T+1 · 6mo ago +0.71%α +0.31% · $92.49
  3. T+5 · 5mo ago +2.36%α +6.18% · $94.00
  4. T+20 · 5mo ago +36.76%α +37.76% · $125.59
  5. T+60 · 3mo ago +8.62%α +6.12% · $99.75

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum Pharmaceuticals CEO Christopher Peetz and Director Saira Ramasastry sold a combined $644K in open-market sales on June 1, 2026, following a cluster of non-cash derivative exercises by multiple directors on May 29. The sales represent ~0.01% of MIRM's $5.9B market cap, trivial in proportion, and are likely liquidity-driven after option exercises, not a bearish signal. The stock has strong analyst support (95% bullish) and the cluster lacks material dollar weight.

Key Financial Metrics

Direction
selling
Total Value
$644.0K
Insiders
2

Key Facts

  • CEO Peetz sold 2,602 shares at $94.64 for $246K on June 1, 2026
  • Director Ramasastry sold 3,977 shares at $100 for $398K on June 1, 2026
  • Both sales followed non-cash derivative exercises on May 29 (directors) and June 1 (CEO)
  • Total open-market sales of $644K represent ~0.01% of MIRM's $5.9B market cap
  • Analyst consensus is 95% bullish (18 Buy, 1 Hold, 0 Sell)
  • No open-market purchases in the cluster

Financial Impact

Total insider sales of $644K, immaterial relative to $5.9B market cap

insider ownershipdilution

Risk Factors

  • Insider sales could accelerate if stock continues to appreciate, but no evidence of coordinated selling
  • No purchases in cluster, lack of bullish insider signal

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MIRM-1780444246058

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026